Today: 21 July 2026
Roper stock slips again after outlook miss; Deltek in focus as U.S. funding deadline nears
28 January 2026
1 min read

Roper stock slips again after outlook miss; Deltek in focus as U.S. funding deadline nears

New York, Jan 28, 2026, 13:23 ET — Regular session

  • Roper shares dipped further, following a sharp decline linked to its 2026 guidance just a day earlier
  • The company reported weaker demand at Deltek, its government contracting software division
  • Traders are focused on Washington’s Jan. 31 funding deadline and a fresh wave of broker calls

Roper Technologies shares slipped roughly 2% in early afternoon trading Wednesday, as the software company’s 2026 forecast missed Wall Street expectations, pushing the stock lower.

This move matters since Tuesday’s guidance reset thrust Deltek back into the spotlight. Investors are now trying to figure out if the hiccup is just a blip or signals a prolonged slowdown in spending by U.S. agencies and government contractors.

Washington now faces yet another funding deadline this weekend, a risk Roper has flagged as a possible headwind for Deltek’s business.

Roper on Tuesday projected 2026 revenue growth around 8%, with adjusted earnings per share expected between $21.30 and $21.55—both figures coming in under analyst forecasts, per LSEG data cited by Reuters. The company also issued first-quarter adjusted EPS guidance of $4.95 to $5.00, falling short of estimates.

The company flagged weaker demand at Deltek, with Reuters noting management’s caution that future U.S. government shutdowns could weigh on the unit. Deltek saw a slowdown in September as agencies paused operations ahead of the latest shutdown.

Roper disclosed its fourth-quarter figures in an SEC filing, showing revenue at $2.06 billion and adjusted diluted EPS of $5.21. The company’s “adjusted” numbers exclude certain items it considers distortions to its core performance. https://www.sec.gov/Archives/edgar/data/88…

CEO Neil Hunn described the outlook as a “more appropriate and balanced” perspective, following a string of disappointing quarters tied to Deltek uncertainty, Reuters reported. https://www.reuters.com/technology/roper-f…

Broker updates keep coming. Stifel’s Brad Reback dropped the stock from “Buy” to “Hold” and slashed his price target from $550 to $385, according to StreetInsider. https://www.streetinsider.com/Analyst+Comm…

The next move could swing either way. Should Deltek demand hold steady and agencies steer clear of another halt in contracting, investors might overlook a revenue miss. But if government activity stumbles again or license sales falter, the company’s hopes for a second-half rebound will face serious doubt.

Traders are focused on Capitol Hill as U.S. funding is set to expire at 12:01 a.m. Eastern on Saturday, Jan. 31. Reuters flagged the risk of a partial government shutdown if Congress fails to pass new funding.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • SpaceX Set to Announce Q2 Results After Shares Fall 45% Since Nasdaq Debut
    July 21, 2026, 5:25 AM EDT. SpaceX is preparing to publish its first public quarterly earnings report on August 4, presenting Q2 figures following its June Nasdaq IPO. The stock has declined by more than 45% from its initial post-IPO peak, last trading at $119.85 compared to a high of $225.64. The earnings announcement also marks the first insider share unlock, which could add to selling activity. Starlink remains the standout with 10.3 million subscribers and 50% revenue growth, even as the AI segment continues to report losses.
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Previous Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Microchip (MCHP) stock jumps after BofA upgrade as chip rally widens
Next Story

Microchip (MCHP) stock jumps after BofA upgrade as chip rally widens

Go toTop